



Myrexis to Present Oral Anti-Interferon Program at American College of Rheumatology/Association of Rheumatology Health Professionals

SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.

Data will be presented on MPI-0485520, a potent and selective oral anti-interferon (OAI) in preclinical development. MPI-0485520 targets I kappa B kinase epsilon (IKK epsilon) and TANK-binding kinase 1 (TBK1), which are required for the initiation of certain inflammatory immune responses involving type-I interferons (IFN alpha/beta).

Title: Inhibition of Cytosolic Nucleic Acid Receptor Pathways Using the Small Molecule IKK epsilon/TBK1 Kinase Inhibitor MPI-0485520

Date & Time: Monday, November 08, 2010; 9 AM - 6 PM

Poster Number: 493

Preclinical studies of MPI-0485520 have demonstrated potent and selective suppression of IFN alpha/beta and other pro-inflammatory cytokines involved in autoimmune disorders such as systemic lupus erythematosus. The compound also exhibits high oral bioavailability and a favorable ADME/PK profile. Additionally, recent publications have identified IKK epsilon as a promising and novel therapeutic target for the treatment of rheumatoid arthritis.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomic drug discovery and clinical and commercial development.

For more information, please visit www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

Forward-looking statement safe harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and potential efficacy of Myrexis' product candidate MPI-0485520. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.
Patrick M. Burke, Ph.D., V.P., Corporate
and Business Development
801-214-7822
investor.relations@myrexis.com

The Ruth Group
Investors
Sara Pellegrino
(646) 536-7002
spellegrino@theruthgroup.com

Media
Jason Rando
(646) 536-7025
jrando@theruthgroup.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.